Business
Baird Medical Announces Preliminary Financial Results for the Six Months Ended June 30, 2024
Total revenues increased to US$13.1 million, representing 13.8% year-over-year growthNet income reached US$4.4 million, representing 85.8% year-over-year
About this update from Baird Medical Investment Holdings Ltd
[{"type":"text","content":"Total revenues increased to US$13.1 million, representing 13.8% year-over-year growthNet income reached US$4.4 million, representing 85.8% year-over-year growth\nGUANGZHOU, China, Oct. 11, 2024 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) (\"Baird Medical\" or the \"Company\"), a leading microwave ablation (\"MWA\") medical device developer and provider in China which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances, today announced its preliminary financial results for the six months ended June 30, 2024 (the \"First Half of 2024\").\n\nFirst Half of 2024 Financial Highlights\nTotal revenues reached US$13.1 million, representing an increase of 13.8% from US$11.5 million in the same period of 2023.Gross profit increased by 20.9% to US$11.5 million from US$9.5 million in the first half of 2023.Operating income was US$5.1 million, representing an increase of 70.0% from US$3.0 million in the same period of 2023.Net income increased by 85.8% to US$4.4 million from US$2.4 million in the first half of 2023.Ms. Haimei Wu, Founder and CEO of Baird Medical, commented, \"Our preliminary results for the first half of 2024 reflect the continued strength of our core business in China and the initial traction we're gaining in the U.S. market. With our recent FDA clearances, we are optimistic about expanding our reach in the United States, where our minimally invasive microwave ablation technology offers a promising alternative to traditional thyroidectomy for patients with benign thyroid tumors. Given that approximately 150,000 thyroidectomies are performed annually in the U.S., we believe there's a substantial opportunity to improve patient outcomes and reduce healthcare costs. As we move forward, we remain committed to innovation and expanding access to our technology, while maintaining a disciplined approach to growth and operational efficiency.\"\nRecent DevelopmentsOn October 1, 2024, the Company announced the completion of its previously announced business combination (the \"Business Combination\") with ExcelFin Acquisition Corp. The listed company resulting from the Business Combination is Baird Medical Investment Holdings Limited, and its shares and warrants commenced trading on the Nasdaq under the ticker symbols \"BDMD\" and \"BDMDW\", respectively, on October 2, 20...